arterial supply of head and neck figure  6 4 table  6 5

... stage of primary) Subsite Percentage of metastases reported in prophylactically treated necks Oral cavity68, 86, 144 , 1 45 , 153 , 159 - 167 >20% Glottic68,1 46 0- 15% Supraglottic 147 - 149 , 151 ,1 54 - 157 8-30% ... clinically N0 neck may be less than 10%.1 54 , 155 ,40 3 The incidence of occult positive nodes at level I and V is low, especially if other nodal levels are uninvolved. 151 ,1 54 , 155 , 158 ,1 84, 4 04- 4 06 A small ... glottic and supraglottic) and clinically N0 neck. 1 46 , 167 ,40 7 ,41 3 Nodal metastases may be bilateral in 27% of patients. 158 Occult disease is most common at neck nodal levels II, III and IV. 151 , 152 ,40 2...

Ngày tải lên: 14/02/2014, 22:20

... Guide to NECK DISSECTION CLASSIFICATION AND TNM STAGING OF HEAD AND NECK CANCER Committee for Head and Neck Surgery and Oncology American Academy of Otolaryngology– Head and Neck Surgery Neck Dissection ... of: Pocket guide to neck dissection classification and TNM staging of head and neck cancer / Committee for Neck Dissection Classification, American Head and Neck Society [and] Committee for Head ... III Sharma, Anand K IV Kies, Merrill S V American Academy of Otolaryngology Head and Neck Surgery Committee for Head and Neck Surgery and Oncology VI American Head and Neck Society Neck Dissection...

Ngày tải lên: 15/03/2014, 00:20

... mucosal surface of the lip DIAGRAM OF THE HEAD AND NECK Oral cavity Oropharynx Larynx Hypopharynx ALL HEAD AND NECK CANCERS DIAGRAM OF THE LYMPH NODES LEVELS IN THE NECK I II III VI IV V NECK DISSECTION ... within two weeks of urgent referral DIAGNOSIS AND STAGING D Fine needle aspiration cytology should be used in the investigation of head and neck masses D All patients with head and neck cancer should ... areas of metastatic disease in patients with head and neck cancer should include: number of involved nodes level of involved nodes extracapsular spread of tumour type of nodal dissection size of...

Ngày tải lên: 15/03/2014, 01:20

... 90.0% IVb 47 57 .2% 0-2 66 .7% 3 -4 51 60 .5% 12 50 .0% 45 57 .3% 60 00 cGy 20 55 .0% > 60 00 cGy 37 64 .5% never 11 63 .6% yes 46 60 .6% 48 66 .7% 60 .1% 0 .61 4 66 .7% 60 .0% 0 .67 9 never 20 70.0% 0 .63 8 74. 0% 0.123 ... Age 50 22 (38 .6% ) 11 (50 .0%) 11 (50 .0%) > 50 35 (61 .4% ) 20 (57 .1%) 15 (42 .9%) 55 ( 96. 5% ) (3 .5% ) 30 ( 54 . 5% ) (50 %) 25 ( 45 .5% ) (50 %) 1.000 0. 057 0 .59 8 0 .47 (0.11, 2.11) 03 15 48 . 36 (0. 54 , 43 13.32) ... negative 12 (21.1%) (41 .7%) (58 .3%) positive 45 (78.9%) 26 (57 .8%) 19 (42 .2%) 0 .50 3 11 (17.2%) 46 (82.8%) ( 36. 4% ) 27 (58 .7%) (63 .6% ) 19 (41 .3%) 0.318 0.2 75 0. 75 (0. 15, 3 . 64 ) 0.727 2 .49 (0.31, 19.88)...

Ngày tải lên: 18/06/2014, 19:20

... 90.0% IVb 47 57 .2% 0-2 66 .7% 3 -4 51 60 .5% 12 50 .0% 45 57 .3% 60 00 cGy 20 55 .0% > 60 00 cGy 37 64 .5% never 11 63 .6% yes 46 60 .6% 48 66 .7% 60 .1% 0 .61 4 66 .7% 60 .0% 0 .67 9 never 20 70.0% 0 .63 8 74. 0% 0.123 ... Age 50 22 (38 .6% ) 11 (50 .0%) 11 (50 .0%) > 50 35 (61 .4% ) 20 (57 .1%) 15 (42 .9%) 55 ( 96. 5% ) (3 .5% ) 30 ( 54 . 5% ) (50 %) 25 ( 45 .5% ) (50 %) 1.000 0. 057 0 .59 8 0 .47 (0.11, 2.11) 03 15 48 . 36 (0. 54 , 43 13.32) ... negative 12 (21.1%) (41 .7%) (58 .3%) positive 45 (78.9%) 26 (57 .8%) 19 (42 .2%) 0 .50 3 11 (17.2%) 46 (82.8%) ( 36. 4% ) 27 (58 .7%) (63 .6% ) 19 (41 .3%) 0.318 0.2 75 0. 75 (0. 15, 3 . 64 ) 0.727 2 .49 (0.31, 19.88)...

Ngày tải lên: 20/06/2014, 03:20

... report of RTOG 961 0, a multiinstitutional trial ofreirradiation and chemotherapy for unresectable 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 recurrent squamous cell carcinoma of the head and neck ... compared 43 cases of 12 .5 Gy SRS and 43 cases of 34 Gy delivered in 2 -6 fractions of SRT The 1- and 3-year local failure-free survival rates were 70% and 51 % for the SRS group and 91% and 83% for the ... bleeding rates of 3- 14% , and a recent IMRT series reported bleeding rates of 0-3% [4, 14, 21, 24] On the other hand, several SRS and hSRT series have reported higher rates (9- 15% ) of bleeding, including...

Ngày tải lên: 09/08/2014, 09:21

... 17.7 65 .9 16. 1 52 .5 5 .4 45. 5 8.7 35. 3 6. 3 17 .4 2.1 9.8 37.0 6. 0 28.9 6. 5 13 .4 1.3 17.8 40 .8 7.1 19 .5 30.3 49 .0 22.2 34. 1 1.7 46 . 3 12.1 20.1 3 .5 8.0 4. 5 1.7 57 .8 2 .6 11.2 17.3 4. 7 4. 0 15. 2 34. 7 ... 11.2 17.3 4. 7 4. 0 15. 2 34. 7 8.9 6. 5 36. 5 78.7 25. 1 60 .2 5 .4 64 .2 13 .5 36. 1 6. 4 17.8 5. 3 9.8 60 .3 6. 2 29 .4 19.8 13.9 5. 0 20.3 61 .8 11.9 19 .5 Discussion The use of FDG-PET/CT prior to treatment ... 23 24 25 26 27 Koshy M, Paulino AC, Howell R, Schuster D, Halkar R, Davis LW: F18FDG-PET/CT fusion in radiotherapy treatment planning for head and neck cancer Head and Neck 20 05, 27 :49 4 -50 2 Wang...

Ngày tải lên: 09/08/2014, 09:22

... Local control % P* 15 56 . 7 73.3 0.3330 10 50 .0 50 .0 66 .7 0. 348 5 14 71 .5 52.8 0.8920 13 63 .5 53.8 0. 94 36 16 60.0 50 .0 0 .4 3 65 12 6 50 .0 66 .7 33.3 0.88 14 12 50 .0 55 .5 0.8 966 13 11 84 .6 0.0007 tion (primarily ... Total 21 45 .0 14. 0 30.0 66 ,0 15 30.0 9.3 25. 0 50 .0 21 21.0 10.3 7.0 42 .0 21 65 .0 11 .6 46 1 05. 0 21 53 .1 13.8 53 .1 86. 1 21 31.0 17.9 13.0 91.0 21 35 .4 10.9 29 ,5 59.0 21 111.2 22.2 62 .2 1 46 . 8 Legend ... Chemotherapy Yes No Total n pacients % 15 71 .4 28 .6 16 76. 2 23.8 10 4. 8 19.0 47 .6 28 .6 12 57 .1 28 .6 14. 3 15 71 .4 28 .6 01 20 4. 8 95. 2 21 100 median 53 .5 Three-dimensional planning CT image reconstruction...

Ngày tải lên: 09/08/2014, 10:21

... 8.8 Mandible Salivary glands Palate 85 60 19 .6 13.9 7.1 5. 0 55 12.7 4 .6 Tonsil 26 6.0 2.2 Cheek 25 5.8 2.1 Tongue 25 5.8 2.1 Floor of mouth 11 2 .5 0.9 Lip 2.1 0.8 Face 32 7 .4 2.7 TOTAL 43 3 100 ... Carcinomas 15- 24 77(8.8%) 238(27.2%) 361 (41 .4% ) 178(20 .4% ) 873*(100%) 46 ( 22%) 32( 15. 3%) 56 ( 26. 8%) 59 (28.2%) 60 (28.7%) 209(100%) 20(18.9%) 34( 32.1%) 35( 33%) 14( 13.2%) 3(2.8%) 1 06( 100%) 1 (50 %) 1 (50 %) ... 1(1 .4% ) 5( 9 .4% ) 25 Tongue 24( 7.7%) 1(1.9%) 25 Tonsil FOM 12(3.9%) 11(3 .5% ) 13(18 .6% ) 1(1.9%) 26 11 Lip Sarcomas 8(2 .6% ) 1(1 .4% ) Mandible 43 (13.9%) 26( 37.1%) 16( 30.2%) 85 Maxilla 63 (20.3%) 22(31 .4% )...

Ngày tải lên: 11/08/2014, 20:21

... 2008, 9:R53 http://genomebiology.com/2008/9/3/R53 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 Genome Biology 2008, 21(9):1010-10 24 Wang E, Lenferink A, O'Connor-McCourt M: Cancer ... 0 .5 * 1 .5 ICAM1 1.0 1.0 * 1.0 * * * 0 .5 * * 0 .5 0 .5 * * 0.0 1 .5 0.0 1 .5 ITGA5 1.0 0.0 1 .5 LAMA3 1.0 1.0 * * 0 .5 * 0 .5 0.0 48 h * * * * * 0 .5 0.0 24 h LAMB3 0.0 24 h 48 h 24 h 48 h Silencing6RELA ... 117 55 250 1 25 197 wt p53-deficient 92 1 24 173 34 mt p53 NFκB1 56 cREL (c) wt p53-deficient up-regulated 70 § wt p53-deficient % of gene number 60 mt p53 50 40 30 20 10 § up-regulated 60 % of...

Ngày tải lên: 14/08/2014, 08:20

... distribution and the prognostic lymph impact node of regional spread from nasopharynx cancer, particularly of the undifferentiated type, are different from those of other head and neck mucosal cancers and ... and neck mucosal cancers and justify the use of a different N classification scheme NX Regional lymph nodes T3 N1 M0 T3 N2 M0 T4 N0 M0 T4 N1 M0 T4 N2 M0 cannot be assessed N0 No regional lymph ... should be performed, with biopsy of all suspicious-appearing areas and directed biopsies of common primary sites, such as the nasopharynx, tonsil, tongue base, and pyriform sinus ...

Ngày tải lên: 07/07/2014, 01:20

... Cefpodoxime 75 100 85 Cefdinir 76 100 85 Ceftriaxone 96 100 94 Cefuroxime 73 83 50 Erythro-clarithromycin 72 100 Telithromycin 84 ? 100 Azithromycin 71 100 Clindamycin 90 0 Doxycycline 80 25 96 Resp quinolones ... Otolaryng., Head, Neck Surg low-resistance risk cases: 20 04; 130:Suppl S 34 ff .6, 7) The likelihood of spontaAmoxicillin (high-dose) with or without neous resolution (without antibiotic therapy) of acute ... hemolytic) 15- 30% prevalent bacterial cause of pharyngitis and the Group C beta-hemolytic strep 5% organism of most concern to clinicians because Mycoplasma pneumoniae ?% of the risk of rheumatic...

Ngày tải lên: 10/08/2014, 18:21

... Modlin, S (19 95) Extraluminal laryngotracheal fixation with absorbable miniplates Arch Otolaryngol Head Neck Surg., 121, 13 56 1 360 59 Pietrzak, W.S., Sarver, D.R., and 60 61 62 63 64 65 66 67 68 Verstynen, ... Surg., 4, 1–11 Greenberg, S.D and Wilms, R.K (1 962 ) Tracheal prosthesis: an experimental study in dogs Arch Otolaryngol., 75, 3 35 371 38 Poticha, S.M and Lewis, F.J (1 966 ) 39 40 41 42 43 44 45 46 47 ... Chem Rev., 108, 1787–17 96 152 Vacanti, C.A (20 06) History of tissue 153 1 54 155 1 56 157 158 159 160 161 162 engineering and a glimpse into its future Tissue Eng., 12, 1137–1 142 Griffith, C.K., Miller,...

Ngày tải lên: 25/10/2013, 08:20

... Int J Dermatol 20 05 ;44 : 64 6 - 64 9 1 45 Arduino PG, Porter SR Oral and perioral herpes simplex virus type (HSV-1) infection: review of its management Oral Dis 20 06; 12:2 54 - 270 1 46 Kolokotronis A, Doumas ... 1999; 353 : 65 5 - 65 6 64 Martins AC, Castro Jde C, Moreira JS A ten-year historic study of paranasal cavity endoscopy in patients with leprosy Rev Bras Otorhinolaryngol (Engl Ed) 20 05; 71 :60 9 -61 5 65 Ridley ... Probes 1992 ;6: 67-77 64 64 Am J Clin Pathol 2007;128: 35 -67 DOI: 10.1309/6BBT12WGNK77N4EH 130 Chidzonga MM HIV/AIDS orofacial lesions in 1 56 Zimbabwean patients at referral oral and maxillofacial clinics...

Ngày tải lên: 19/02/2014, 08:20

... ( 34. 8) 15 ( 65 .2) 13 (81.3) (18.7) (12 .5) 14 (87 .5) (100) (0.0) ( 25. 0) ( 75. 0) 85 ( 95. 5) 208 (90 .4) (4. 5) 22 (9 .6) 24 (27.0) 54 (23 .5) 65 (73.0) 1 76 ( 76. 5) 51 ( 86. 4) 0.021 21 (7.2) 82 ( 86. 3) 0 .55 7 ... - 95 0. 866 60 .0 63 .1 20 - 95 41 - 81 0. 140 61 61 24 - 95 20 - 88 66 (22.3) 227 (77.7) 22 (23.2) 0.972 73 ( 76. 8) Gender Male 217 ( 74. 3) 75 ( 25. 7) 66 (69 .5) 29 (30 .5) Larynx 137 ( 74. 9) 46 ( 25. 1) ... (92.8) 0. 052 (13 .6) ( 15. 3) 50 ( 84. 7) 82 (22 .6) 281 (77 .4) (31.2) 11 (68 .8) 0. 3 45 0. 150 0.8 56 0. 54 1 0. 244 Lymph node metastasis2 0. 343 331 (91.2) 32 (8.8) 14 (87 .5) (12 .5) 0 .43 0 0.2 95 Histological...

Ngày tải lên: 18/06/2014, 22:20

... ( 34. 8) 15 ( 65 .2) 13 (81.3) (18.7) (12 .5) 14 (87 .5) (100) (0.0) ( 25. 0) ( 75. 0) 85 ( 95. 5) 208 (90 .4) (4. 5) 22 (9 .6) 24 (27.0) 54 (23 .5) 65 (73.0) 1 76 ( 76. 5) 51 ( 86. 4) 0.021 21 (7.2) 82 ( 86. 3) 0 .55 7 ... - 95 0. 866 60 .0 63 .1 20 - 95 41 - 81 0. 140 61 61 24 - 95 20 - 88 66 (22.3) 227 (77.7) 22 (23.2) 0.972 73 ( 76. 8) Gender Male 217 ( 74. 3) 75 ( 25. 7) 66 (69 .5) 29 (30 .5) Larynx 137 ( 74. 9) 46 ( 25. 1) ... (92.8) 0. 052 (13 .6) ( 15. 3) 50 ( 84. 7) 82 (22 .6) 281 (77 .4) (31.2) 11 (68 .8) 0. 3 45 0. 150 0.8 56 0. 54 1 0. 244 Lymph node metastasis2 0. 343 331 (91.2) 32 (8.8) 14 (87 .5) (12 .5) 0 .43 0 0.2 95 Histological...

Ngày tải lên: 20/06/2014, 04:20

... patients with oral cancer (OC) and a control group (CON) 70 60 50 40 OC LE CON 30 20 WR mean ± standard deviation in % 50 ± 19 48 ± 14 76 ± WR min.; max in % 8; 82 17; 74 60 ; 91 10 0-gram 1-gram 2-gram ... Figures and 4) Discussion During and after therapy of malignant diseases of the head and neck, communication skills are of special interest Until now, no objective method with low effort and costs ... influence of therapy options such as different surgical procedures and nonsurgical therapies on communication EURASIP Journal on Audio, Speech, and Music Processing 4. 5 Intelligibility 3 .5 2 .5 1 .5 0.5...

Ngày tải lên: 21/06/2014, 20:20

... Diseases of the Maxillofacial Bones 1 04 4.3 4. 3.1 4. 3.1.1 4. 3.1.2 4. 3.2 4. 3.2.1 4. 3.2.2 4. 3.2.3 4. 3.2 .4 4.3.2 .5 4. 3.3 4. 3.3.1 4. 3.3.2 4. 3.3.3 4. 3 .4 4.3 .4. 1 4. 3 .4. 2 4. 4 4. 4.1 4. 4.1.1 4. 4.1.2 4. 4.1.3 ... 5. 9.11.2 Carcinosarcoma Ex Pleomorphic Adenoma 137 137 5. 14. 1 5. 14. 2 140 140 141 142 143 143 144 144 144 144 144 144 1 46 147 148 5. 14. 3 5. 15 5. 16 ... 6. 2.7.2 Sarcoma 6. 3 6. 3.1 6. 3.2 6. 3.3 6. 3.3.1 6. 3.3.2 6. 3 .4 6. 3 .4. 1 6. 3 .4. 2 6. 3 .5 6. 3 .6 6.3 .6. 1 6. 3 .6. 2 6. 3 .6. 3 6. 3 .6. 4 6. 3 .6. 5 6. 3.7 Waldeyer’s Ring Anatomy and...

Ngày tải lên: 29/06/2014, 09:20

... Engl J Med 350 :1 9 45 , 20 04 [PMID: 151 288 94] Bonner JA et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 3 54 : 56 7 , 20 06 [PMID: 1 64 67 54 4 ] Brockstein ... chemoradiotherapy for head and neck cancer Semin Oncol 31:7 86, 20 04 [PMID: 155 998 56 ] Cohen EE et al: The expanding role of systemic therapy in head and neck cancer J Clin Oncol 22:1 743 , 20 04 [PMID: 151 17998] ... Oncol 4: 1 45 , 2007 Slebos RJ et al: Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma Clin Cancer Res 12:701, 20 06 [PMID: 1 64 67079]...

Ngày tải lên: 07/07/2014, 01:20